Kim Brown, CEO, Compass Biomedical | Onyx Live | ISCT Dublin 2026
Everyone watches the final cell therapy – far fewer watch what the cells are grown in. Compass Biomedical's Kim Brown on why culture media quietly shapes the product.
Jason Jones, Head of Global Business Development, Cellular Origins | Onyx Live | ISCT Dublin 2026
Cell and gene therapy can get treatments approved – scaling them is the hard part. Cellular Origins' Jason Jones on automating manufacturing to reach 100,000 patients a year.
Dimitrios Kouroupis, Professor, University of Miami | Onyx Live | ISCT Dublin 2026
Exosomes are "cell therapy without the cells" – and University of Miami's Dimitrios Kouroupis sees these cell-free vesicles reshaping musculoskeletal medicine.
Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026
Fewer than 10% of eligible CAR-T patients ever get treated. Trenchant BioSystems CEO Jon Ellis says the bottleneck is no longer the science – it's manufacturing.
Sean Werner, CTO, BioLife Solutions | Onyx Live | ISCT Dublin 2026
Most cell therapies arrive at the patient frozen – and BioLife Solutions CTO Sean Werner says the field still treats what happens after manufacturing as an afterthought.
Augustin de Bettignies, Chief Business Officer, MPC Therapeutics | Onyx Live | ISCT Dublin 2026
Most of cell therapy fixates on the cell's target. MPC Therapeutics' Augustin de Bettignies says its metabolism — what it burns during manufacturing — matters just as much.
Stephen Sullivan, Founder & Managing Director, Lindville Bio | Onyx Live | ISCT Dublin 2026
Most cell therapies don't fail at the finish line – they fail at the start, says iPSC consultant Stephen Sullivan. Why early decisions decide late outcomes.
Jeff Galecke, Managing Partner, i5 BioPartners | Onyx Live | ISCT Dublin 2026
The cell and gene therapy tools companies that scale aren't always the ones with the best technology, says i5 BioPartners' Jeff Galecke – they're the ones that can tell a clear story.
Sven Kili, Partner, Saisei Ventures | Onyx Live | Cell & Gene Meeting on the Med 2026
Great science isn't enough to get funded, says investor Sven Kili – only great medicines are. Inside the CGT funding squeeze, and what specialist VCs actually screen for.
Bruce Levine, Co-inventor of Kymriah, University of Pennsylvania | Onyx Live | ISCT Dublin 2026
Nine years after Kymriah, the first ever CAR-T cell therapy, was approved, around 10,000 patients have been treated. Inside CAR-T’s next decade with co-inventor Bruce Levine.
Miguel Forte, President, ISCT | Onyx Live | ISCT Dublin 2026
Cell and gene therapy is having its golden age, says ISCT President Miguel Forte – and is still in adolescence. Inside the field's reshaping priorities.
Lisa Deschamps, CEO, AviadoBio | Onyx Live | Cell & Gene Meeting on the Med 2026
AviadoBio is running three CNS gene therapy programs and recently announced a capsid partnership with Apertura to take its silencing platform from rare disease into Alzheimer's.
Marion Hitchcock, Managing Director, Gene & Cell Therapies Incubator Berlin | Onyx Live | Cell & Gene Meeting on the Med 2026
In cell and gene therapy, the science is rarely the bottleneck – making it at scale is. Inside the Bayer–Charité incubator betting on Berlin to fix that.
Faraz Ali, CEO, Tenaya Therapeutics | Onyx Live | Cell & Gene Meeting on the Med 2026
Heart disease kills more people than every cancer combined. Inside Tenaya's bet that the precision-medicine playbook oncology pioneered will work on the heart, too.
Bernd Mühlenweg, CBO/CFO, Cellbox Solutions | Onyx Live | Cell & Gene Meeting on the Med 2026
More and more cell types cannot be frozen anymore. If you think about organoids, mixed cultures, artificial tissues – all of those require warm chain logistics.
Sarmitha Sathiamoorthy, President & Founder, AspireBio Consulting | Onyx Live | Cell & Gene Meeting on the Med 2026
In a funding-constrained biotech market, most early-stage teams still try to reinvent the AAV and advanced-therapy CMC playbooks the industry has already solved a dozen times over.